Sinclair has reported £8.9m of sales in the first quarter of the calendar year, and re-iterated guidance of 40% YoY top line growth for calendar 2016 (equivalent to £35m of sales, not including the expected contribution from the USA and Brazil), providing strong support for our current forecasts. In addition, the news of a US distribution agreement for Silhouette Instalift™ with Thermi (Almirall) is exciting: we are looking forward to the imminent launch of the product, which represents a key dr ....

20 May 2016
Offer period ends; Q1 trading strong; US deal signed for Silhouette

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Offer period ends; Q1 trading strong; US deal signed for Silhouette
Sinclair Pharma (SPH:LON) | 0 0 0.6% | Mkt Cap: 111.5m
- Published:
20 May 2016 -
Author:
Singer CM Team -
Pages:
3 -
Sinclair has reported £8.9m of sales in the first quarter of the calendar year, and re-iterated guidance of 40% YoY top line growth for calendar 2016 (equivalent to £35m of sales, not including the expected contribution from the USA and Brazil), providing strong support for our current forecasts. In addition, the news of a US distribution agreement for Silhouette Instalift™ with Thermi (Almirall) is exciting: we are looking forward to the imminent launch of the product, which represents a key dr ....